Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-26T15:59:36.205Z Has data issue: false hasContentIssue false

Synergistic antinociception between zaprinast and morphine in the spinal cord of rats on the formalin test

Published online by Cambridge University Press:  23 December 2005

M. H. Yoon
Affiliation:
Chonnam National University, Medical School, Department of Anesthesiology and Pain Medicine, Gwangju, Korea
J. I. Choi
Affiliation:
Chonnam National University, Medical School, Department of Anesthesiology and Pain Medicine, Gwangju, Korea
S. J. Kim
Affiliation:
Chonnam National University, Medical School, Department of Anesthesiology and Pain Medicine, Gwangju, Korea
C. M. Kim
Affiliation:
Chonnam National University, Medical School, Department of Anesthesiology and Pain Medicine, Gwangju, Korea
H. B. Bae
Affiliation:
Chonnam National University, Medical School, Department of Anesthesiology and Pain Medicine, Gwangju, Korea
S. T. Chung
Affiliation:
Chonnam National University, Medical School, Department of Anesthesiology and Pain Medicine, Gwangju, Korea
Get access

Extract

Summary

Background and objective: The cyclic guanosine monophosphate level, which causes an antinociception, is increased in cells as a direct result of phosphodiesterase inhibition. This study used a nociceptive test to examine the nature of the pharmacological interaction between intrathecal zaprinast, a phosphodiesterase inhibitor, and morphine. Methods: Catheters were inserted into the intrathecal space through an incision in the atlantooccipital membrane of male Sprague–Dawley rats. As a nociceptive model, 50 μL of a 5% formalin solution was injected into the hind paw. After observing the effect of zaprinast (37, 111, 369 nmol) and morphine (1, 4, 10, 40 nmol) alone, the interactions of their combination were examined by an isobolographic analysis. Results: Intrathecal zaprinast (P < 0.05) and morphine (P < 0.05) dose-dependently suppressed the flinching observed during phase 1 and phase 2 in the formalin test. The ED50 values (95% confidence intervals) of zaprinast and morphine in phase 1 were 161.9 (87.9–298.3) and 11.6 nmol (4.8–27.9 nmol), respectively. The phase 2 ED50 values (95% confidence intervals) of zaprinast and morphine were 229.9 (142.5–370.9) and 3.9 nmol (1.9–7.6 nmol), respectively. Isobolographic analysis revealed a synergistic interaction after intrathecal delivery a zaprinast–morphine mixture in both phases. The ED50 values of (95% confidence intervals) zaprinast in the combination of zaprinast with morphine in phase 1 and phase 2 were 14.2 (4.9–40.6) and 10.4 nmol (3–35.9 nmol), respectively. Conclusions: Intrathecal zaprinast and morphine are effective against acute pain and facilitated pain state. Zaprinast interacts synergistically with morphine.

Type
Original Article
Copyright
© 2006 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ferreira SH, Nakamura M. Prostaglandin hyperalgesia, a cAMP/Ca2+ dependent process. Prostaglandins 1979; 18: 179190.Google Scholar
Sousa AM, Prado WA. The dual effect of a nitric oxide donor in nociception. Brain Res 2001; 897: 919.Google Scholar
Pyne NJ, Arshavsky V, Lochhead A. cGMP signal termination. Biochem Soc Trans 1996; 24: 10191022.Google Scholar
Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75: 725748.Google Scholar
Mixcoatl-Zecuatl T, Aguirre-Banuelos P, Granados-Soto V. Sildenafil produces antinociception and increases morphine antinociception in the formalin test. Eur J Pharmacol 2000; 400: 8187.Google Scholar
Jain NK, Patil CS, Singh A, Kulkarni SK. Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Res 2001; 909: 170178.Google Scholar
Asomoza-Espinosa R, Alonso-Lopez R, Mixcoatl-Zecuatl T, Aguirre-Banuelos P, Torres-Lopez JE, Granados-Soto V. Sildenafil increases diclofenac antinociception in the formalin test. Eur J Pharmacol 2001; 418: 195200.Google Scholar
Jain NK, Patil CS, Singh A, Kulkarni SK. Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology 2003; 67: 150156.Google Scholar
Patil CS, Jain NK, Singh A, Kulkarni SK. Modulatory effect of cyclooxygenase inhibitors on sildenafil-induced antinociception. Pharmacology 2003; 69: 183189.Google Scholar
Cunha FQ, Teixeira MM, Ferreira SH. Pharmacological modulation of secondary mediator systems – cyclic AMP and cyclic GMP – on inflammatory hyperalgesia. Br J Pharmacol 1999; 127: 671678.Google Scholar
Amarante LH, Duarte ID. The kappa-opioid agonist (+/−)-bremazocine elicits peripheral antinociception by activation of the L-arginine/nitric oxide/cyclic GMP pathway. Eur J Pharmacol 2002; 454: 1923.Google Scholar
Jeong CY, Choi JI, Yoon MH. Roles of serotonin receptor subtypes for the antinociception of 5-HT in the spinal cord of rats. Eur J Pharmacol 2004; 502: 205211.Google Scholar
Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 17: 10311036.Google Scholar
Coderre TJ, Yashpal K. Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. Eur J Neurosci 1994; 6: 13281334.Google Scholar
Okuda K, Sakurada C, Takahashi M, Yamada T, Sakurada T. Characterization of nociceptive responses and spinal releases of nitric oxide metabolites and glutamate evoked by different concentrations of formalin in rats. Pain 2001; 92: 107115.Google Scholar
Malmber AB, Yaksh TL. Isobolographic and dose–response analyses of the interaction between intrathecal mu and delta agonists: effects of naltrindole and its benzofuran analog (NTB). J Pharmacol Exp Ther 1992; 263: 264275.Google Scholar
Yoon MH, Choi JI. Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology 2003; 99: 701707.Google Scholar
Tallarida RJ, Porreca F, Cowan A. Statistical analysis of drug–drug and site–site interactions with isobolograms. Life Sci 1989; 45: 99479961.Google Scholar
Roerig SC, Fujimoto JM. Morphine antinociception in different strains of mice: relationship of supraspinal–spinal multiplicative interaction to tolerance. J Pharmacol Exp Ther 1988; 247: 603608.Google Scholar
Nishiyama T. Interaction between intrathecal morphine and glutamate receptor antagonists in formalin test. Eur J Pharmacol 2000; 395: 203210.Google Scholar
Tallarida RJ, Murray RB. Manual of Pharmacologic Calculations with Computer Programs, 2nd edn. New York, USA: Springer-Verlag, 1987.
Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990; 11: 150155.Google Scholar
Moreland RB, Goldstein II, Kim NN, Traish A. Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor. Trends Endocrinol Metab 1999; 10: 97104.Google Scholar
Przesmycki K, Dzieciuch JA, Czuczwar SJ, Kleinrok Z. Isobolographic analysis of interaction between intrathecal morphine and clonidine in the formalin test in rats. Eur J Pharmacol 1997; 337: 1117.Google Scholar
Duale C, Raboisson P, Molat JL, Dallel R. Systemic morphine reduces the wind-up of trigeminal nociceptive neurons. Neuroreport 2001; 12: 20912096.Google Scholar
Ferreira SH, Duarte IDG, Lorenzetti BB. The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur J Pharmacol 1991; 201: 121122.Google Scholar
Granados-Soto V, Rufino MO, Gomes Lopes LD, Ferreira SH. Evidence for the involvement of the nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test. Eur J Pharmacol 1997; 340: 177180.Google Scholar
Minneman KP, Iversen IL. Enkephalin and opiate narcotics increase cyclic GMP accumulation in slices of rat neostriatum. Nature 1976; 262: 313314.Google Scholar